Erythropoietin alleviates lung ischemia-reperfusion injury by activating the FGF23/FGFR4/ERK signaling pathway.
| Autor: | Jin X; Pulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China., Jin W; Department of Neonatology, Hangzhou Children's Hospital, Hangzhou, China., Li G; Pulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China., Zheng J; Pulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China., Xu X; Pulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | PeerJ [PeerJ] 2024 Mar 27; Vol. 12, pp. e17123. Date of Electronic Publication: 2024 Mar 27 (Print Publication: 2024). |
| DOI: | 10.7717/peerj.17123 |
| Abstrakt: | Background: The purpose of the present study was to investigate the effect of erythropoietin (EPO) on lung ischemia-reperfusion injury (LIRI). Methods: Sprague Dawley rats and BEAS-2B cells were employed to construct an ischemia-reperfusion (I/R)-induced model in vivo and in vitro , respectively. Afterward, I/R rats and tert-butyl hydroperoxide (TBHP)-induced cells were treated with different concentrations of EPO. Furthermore, 40 patients with LIRI and healthy controls were enrolled in the study. Results: It was observed that lung tissue damage, cell apoptosis and the expression of BAX and caspase-3 were higher in the LIRI model in vivo and in vitro than in the control group, nevertheless, the Bcl-2, FGF23 and FGFR4 expression level was lower than in the control group. EPO administration significantly reduced lung tissue damage and cell apoptosis while also up-regulating the expression of FGF23 and FGFR4. Rescue experiments indicated that EPO exerted a protective role associated with the FGF23/FGFR4/p-ERK1/2 signal pathway. Notably, the expression of serum EPO, FGF23, FGFR4 and Bcl-2 was decreased in patients with LIRI, while the expression of caspase-3 and BAX was higher. Conclusion: EPO could effectively improve LIRI, which might be related to the activation of the FGF23/FGFR4/p-ERK1/2 signaling pathway. Competing Interests: The authors declare there are no competing interests. (©2024 Jin et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|